-
1 Comment
Helius Medical Technologies, Inc is currently in a long term downtrend where the price is trading 97.7% below its 200 day moving average.
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 31.9.
Helius Medical Technologies, Inc's total revenue sank by 12.7% to $131K since the same quarter in the previous year.
Its net income has increased by 37.8% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 51.0% to $-3M since the same quarter in the previous year.
Based on the above factors, Helius Medical Technologies, Inc gets an overall score of 3/5.
| Sector | Healthcare |
|---|---|
| Industry | Medical Devices |
| Exchange | F |
| CurrencyCode | EUR |
| ISIN | None |
| Beta | 0.77 |
|---|---|
| Market Cap | 14M |
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | None |
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator (PoNS), a medical device in Canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury. Its PoNS device treats neurostimulation of cranial nerves via the tongue to restore lost function. The company is headquartered in Newtown, Pennsylvania.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 26H1.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
